Patents Represented by Attorney Paul M. Misiak
-
Patent number: 8227447Abstract: Immunostimulatory polymers that contain certain sequence-dependent immunostimulatory RNA motifs and methods for the use of such immunostimulatory polymers and compositions containing such polymers are provided according to the invention. The sequence-dependent immunostimulatory RNA motifs and the polymers incorporating such motifs are potent and selective inducers of TLR7 and the TLR7-associated cytokine IFN-?.Type: GrantFiled: January 30, 2012Date of Patent: July 24, 2012Assignee: Coley Pharmaceutical GmbHInventors: Marion Jurk, Jorg Vollmer
-
Patent number: 8183230Abstract: The present invention is directed to pharmaceutical compositions containing a therapeutically effective amount of an Active Pharmaceutical Ingredient (“API”), a pharmaceutically acceptable cyclodextrin and a pharmaceutically acceptable preservative. The invention is also directed to pharmaceutical compositions of the compounds of Formula (I) wherein R2 is selected from the group consisting of methyl, ethyl, isopropyl, sec-butyl and tert-butyl and a pharmaceutically acceptable cyclodextrin and preservative. Formula (I): In particular, the invention is directed to pharmaceutical compositions of the compound of Formula 1a, and a pharmaceutically acceptable cyclodextrin and a preservative.Type: GrantFiled: January 17, 2005Date of Patent: May 22, 2012Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Roger C. Adami, Frederick David, Julia Ann Wood
-
Patent number: 8128944Abstract: Immunostimulatory polymers that contain certain sequence-dependent immunostimulatory RNA motifs and methods for the use of such immunostimulatory polymers and compositions containing such polymers are provided according to the invention. The sequence-dependent immunostimulatory RNA motifs and the polymers incorporating such motifs are potent and selective inducers of TLR7 and the TLR7-associated cytokine IFN-?.Type: GrantFiled: August 8, 2008Date of Patent: March 6, 2012Assignee: Coley Pharmaceutical GmbHInventors: Marion Jurk, Jorg Vollmer
-
Patent number: 8084486Abstract: This invention relates to a combination product comprising a compound of formula I wherein X, R1, R2, R3, R4, R5, R6, R7 and R9 are as described herein, and one or more further biologically active compounds as described herein, particularly anti-parasitic agents.Type: GrantFiled: April 19, 2011Date of Patent: December 27, 2011Assignee: Pfizer LimitedInventors: Denis Billen, Nathan Anthony Logan Chubb, David Morris Gethin, Kim Thomas Hall, Lee Richard Roberts, Nigel Derek Arthur Walshe
-
Patent number: 8008078Abstract: The present invention relates to polynucleotide molecules comprising nucleotide sequences encoding an aveC gene product, which polynucleotide molecules can be used to alter the ratio or amount of class 2:1 avermectins produced in fermentation cultures of S. avermitilis. The present invention further relates to vectors, host cells, and mutant strains of S. avermitilis in which the aveC gene has been inactivated, or mutated so as to change the ratio or amount of class 2:1 avermectins produced.Type: GrantFiled: April 23, 2008Date of Patent: August 30, 2011Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Kim J. Stutzman-Engwall, Anke Krebber, Claes Gustafsson, Jeremy S. Minshull, Sun Ai Raillard, Seran Kim, Yan Chen
-
Patent number: 7968584Abstract: This invention relates to a range of 1-aryl-4-cyclopropylpyrazoles in which the cyclopropyl ring is substituted at the angular position, and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes to their synthesis and their use as parasiticides.Type: GrantFiled: March 19, 2009Date of Patent: June 28, 2011Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Denis Billen, Jessica Boyle, Douglas James Critcher, David Morris Gethin, Kim Thomas Hall, Graham Michael Kyne
-
Patent number: 7960426Abstract: This invention relates to a combination product comprising a compound of formula I wherein X, R1, R2, R3, R4, R5, R6, R7 and R9 are as described herein, and one or more further biologically active compounds as described herein, particularly anti-parasitic agents.Type: GrantFiled: February 3, 2009Date of Patent: June 14, 2011Assignee: Pfizer LimitedInventors: Denis Billen, Nathan Anthony Logan Chubb, David Morris Gethin, Kim Thomas Hall, Lee Richard Roberts, Nigel Derek Arthur Walshe
-
Patent number: 7825149Abstract: This invention relates to a range of alpha substituted 2-benzyl substituted imidazole compounds and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes for their synthesis and their use as parasiticides.Type: GrantFiled: August 4, 2009Date of Patent: November 2, 2010Assignee: Pfizer LimitedInventors: Nathan Anthony Logan Chubb, Mark Roger Cox, Jerome Sebastien Dauvergne, Richard Andrew Ewin, Christelle Lauret
-
Patent number: 7803832Abstract: The invention relates to a sulfonamide compound of formula (I) or a pharmaceutically, veterinarily or agriculturally acceptable salt or solvate thereof, where the groups R1-R5 are described in the description, to compositions comprising such compounds, processes for their synthesis and their use as parasiticides.Type: GrantFiled: December 1, 2009Date of Patent: September 28, 2010Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Douglas James Critcher, Nigel Derek Arthur Walshe, Christelle Lauret
-
Patent number: 7662949Abstract: The invention provides immunostimulatory compositions and use of those compounds in the preparation of medicaments for the treatment of disease as well as in vitro uses. In particular, the compositions of the invention include immunostimulatory oligoribonucleotides that incorporate a sequence-dependent immunostimulatory sequence motif. Specific modifications involving phosphate linkages, nucleotide analogs, adducts, and combinations thereof are provided. Compositions of the invention, which optionally can include an antigen, can be used alone or together with other treatments to stimulate or enhance an immune response. Also provided are compositions and methods useful for treating a subject having an infection, a cancer, an allergic condition, asthma, airway remodeling, or immunodeficiency. Immunostimulatory oligoribonucleotides of the invention are believed to stimulate Toll-like receptor 8 (TLR8).Type: GrantFiled: November 22, 2006Date of Patent: February 16, 2010Assignees: Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Inc.Inventors: Alexandra Forsbach, Jörg Vollmer, Grayson B. Lipford
-
Patent number: 7538134Abstract: This invention relates to a range of 1-aryl-4-cyclopropylpyrazoles in which the cyclopropyl ring is substituted at the angular position, and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes to their synthesis and their use as parasiticides.Type: GrantFiled: June 14, 2006Date of Patent: May 26, 2009Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Denis Billen, Jessica Boyle, Douglas James Critcher, David Morris Gethin, Kim Thomas Hall, Graham Michael Kyne
-
Patent number: 7482368Abstract: The invention relates to triamide MTP/ApoB inhibitors of the formula 1 wherein R1-R8 are as defined in the specification, as well as pharmaceutical compositions and uses thereof, and processes for preparing the compounds. The compounds of the invention are useful for the treatment of obesity and lipid disorders.Type: GrantFiled: August 2, 2005Date of Patent: January 27, 2009Assignee: Pfizer IncInventors: Peter Bertinato, Brian Bronk, Alan E. Blize, Hengmiao Cheng, Jin Li, Hiep Huatan, Clive Mason